Targeting chromatin modifiers for the treatment of medical conditions
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsMichael F. Clarke, Maddalena Adorno
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for the treatment of medical conditions associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal. Aspects of the methods include inhibiting H2A deubiquitinating enzyme activity in cells, e.g. by administering an effective amount of an H2A deubiquitinating enzyme antagonist. Also provided are screens to identify therapeutics for the treatment of medical conditions associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal.
Claims14
A method of treating a medical condition associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal, the method comprising:
- administering an effective amount of an antagonist of H2A deubiquitinating enzyme USP16 to the individual, wherein the antagonist reduces the amount of USP16 in a cell or binds directly to USP16.
Dependencies are inferred from the claim text.